<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; UDFDA</title>
	<atom:link href="http://www.tapanray.in/tag/udfda/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>The Relevance of Content Marketing In Pharma</title>
		<link>http://www.tapanray.in/the-relevance-of-content-marketing-in-pharma/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-relevance-of-content-marketing-in-pharma</link>
		<comments>http://www.tapanray.in/the-relevance-of-content-marketing-in-pharma/#comments</comments>
		<pubDate>Sun, 11 Jun 2017 23:49:47 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[bans]]></category>
		<category><![CDATA[CME]]></category>
		<category><![CDATA[content]]></category>
		<category><![CDATA[environment]]></category>
		<category><![CDATA[import]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[pressure]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Relevance]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UDFDA]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8268</guid>
		<description><![CDATA[“Nearly half of pharma industry may come under price control” – was the headline of a media report of June 7, 2017. Although, National Pharmaceutical Pricing Authority (NPPA) has apparently denied any such move, the fact is that the number &#8230; <a href="http://www.tapanray.in/the-relevance-of-content-marketing-in-pharma/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-relevance-of-content-marketing-in-pharma/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Big Pharma’s Windfall Gain From Indian Pharma’s Loss, Costs American Patients Dear</title>
		<link>http://www.tapanray.in/big-pharmas-windfall-gain-from-indian-pharmas-loss-costs-american-patients-dear/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=big-pharmas-windfall-gain-from-indian-pharmas-loss-costs-american-patients-dear</link>
		<comments>http://www.tapanray.in/big-pharmas-windfall-gain-from-indian-pharmas-loss-costs-american-patients-dear/#comments</comments>
		<pubDate>Thu, 19 Jun 2014 09:23:48 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AstraZeneca]]></category>
		<category><![CDATA[big]]></category>
		<category><![CDATA[Diovan]]></category>
		<category><![CDATA[gain]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[loss]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[nexium]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[quagmire]]></category>
		<category><![CDATA[Ranbaxy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[UDFDA]]></category>
		<category><![CDATA[Valcyte]]></category>
		<category><![CDATA[Windfall]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5540</guid>
		<description><![CDATA[According to US-FDA, its ‘Import Bans’ on quality grounds of the drugs manufactured at various Indian facilities, such as, Ranbaxy’s Paonta Sahib, Dewas and Mohali and Toansa plants, were reportedly solely directed at negating the health safety risks of American patients &#8230; <a href="http://www.tapanray.in/big-pharmas-windfall-gain-from-indian-pharmas-loss-costs-american-patients-dear/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/big-pharmas-windfall-gain-from-indian-pharmas-loss-costs-american-patients-dear/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
